- Home
- OTLK vs CCEL Comparison
OTLK vs CCEL Comparison
Compare OTLK & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- CCEL
- Stock Information
- Founded
- OTLK 2010
- CCEL 1989
- Country
- OTLK United States
- CCEL United States
- Employees
- OTLK N/A
- CCEL N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- CCEL Managed Health Care
- Sector
- OTLK Health Care
- CCEL Health Care
- Exchange
- OTLK Nasdaq
- CCEL Nasdaq
- Market Cap
- OTLK 48.3M
- CCEL 39.9M
- IPO Year
- OTLK 2016
- CCEL 1997
- Fundamental
- Price
- OTLK $2.25
- CCEL $4.81
- Analyst Decision
- OTLK Strong Buy
- CCEL Strong Buy
- Analyst Count
- OTLK 5
- CCEL 1
- Target Price
- OTLK $9.60
- CCEL $8.50
- AVG Volume (30 Days)
- OTLK 987.3K
- CCEL 14.5K
- Earning Date
- OTLK 08-13-2025
- CCEL 07-15-2025
- Dividend Yield
- OTLK N/A
- CCEL 12.42%
- EPS Growth
- OTLK N/A
- CCEL N/A
- EPS
- OTLK 0.83
- CCEL N/A
- Revenue
- OTLK N/A
- CCEL $31,988,783.00
- Revenue This Year
- OTLK N/A
- CCEL $2.49
- Revenue Next Year
- OTLK $419.06
- CCEL $0.95
- P/E Ratio
- OTLK $2.62
- CCEL N/A
- Revenue Growth
- OTLK N/A
- CCEL 1.10
- 52 Week Low
- OTLK $0.87
- CCEL $4.68
- 52 Week High
- OTLK $9.10
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- OTLK 67.03
- CCEL 43.31
- Support Level
- OTLK $2.16
- CCEL $4.75
- Resistance Level
- OTLK $2.45
- CCEL $5.05
- Average True Range (ATR)
- OTLK 0.16
- CCEL 0.19
- MACD
- OTLK 0.05
- CCEL -0.01
- Stochastic Oscillator
- OTLK 81.01
- CCEL 14.71
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.